Olema Pharmaceuticals, Inc.

This study tests a new drug, palazestrant, combined with ribociclib against the standard letrozole with ribociclib for people with ER+, HER2- advanced breast cancer that has not been treated before. About 1,000 adults with locally advanced or metastatic breast cancer will take pa…

This study tests a new drug called OP-1250 (palazestrant) against standard treatments (fulvestrant or an aromatase inhibitor) in 510 people with a common type of advanced breast cancer (ER+, HER2-). Participants must have already tried hormone therapy plus a CDK4/6 inhibitor. The…

This early-phase study tests a new drug called OP-3136 in adults with advanced breast, lung, or prostate cancer that has spread or no longer responds to standard treatments. The goal is to find a safe dose and see if the drug, alone or with other cancer medicines, can shrink tumo…

This study tests a new drug called OP-1250 (Palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. About 190 adults will receive one of four drug combinations to find the safest dose and understand side…